Inventiv Health Inc

Inventiv Health — Q2 2015 Earnings Presentation

16 slides from Inventiv Health's earnings presentation, Aug 14, 2015

  1. Slide 1: inVentiv Health Second Quarter 2015 Earnings Presentation

    Exhibit 99.1 inVentiv Health Second Quarter 2015 Earnings Presentation Aug 17, 2015

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect o

  3. Slide 3: Quarterly Highlights

    Quarterly Highlights Strong financial performance in Q2 builds on recent momentum Organic revenue (1) growth of 12% (9% reported net revenue growth) Adjusted EBITDA(2) growth of 32% to $62mm Q2 benefited from timing within the year of certain items Year-to-date organic revenue (1) and Adjusted EBITD

  4. Slide 4: Clinical Update

    Clinical Update Organic Revenue (1) growth of 11% (7% reported net revenue growth) Backlog conversion accelerating on full service projects Growth is strongest in full service space Strategic resourcing revenues expected to accelerate in second half Miami clinic will come on-line in January; first s

  5. Slide 5: Commercial Update

    Commercial Update Acceleration of performance in Q2 Organic Revenue (1) growth of 13% (11% reported net revenue growth) Adjusted EBITDA(2) growth of 40% Selling solutions business strength continues Record volume of new teams launched in quarter Additional margin enhancements realized in communicati

  6. Slide 6: Consolidated inVentiv Health Q2 2015 Financial Update

    Consolidated inVentiv Health Q2 2015 Financial Update Net Revenues(1) ($ millions) $489 $940 $450 $871 Q2 2014 Q2 2015 YTD 2014 YTD 2015 Adjusted EBITDA(2) ($ millions) $62 $114 $47 $90 Q2 2014 Q2 2015 YTD 2014 YTD 2015 (1) The sum of the segments do not reconcile to Consolidated inVentiv Health due

  7. Slide 7: Clinical Performance

    Clinical Performance Net Revenues(1) ($ millions) $234 $453 $218 $433 Q2 2014 Q2 2015 YTD 2014 YTD 2015 Adjusted EBITDA(2) $56 ($ millions) $29 $47 $22 Q2 2014 Q2 2015 YTD 2014 YTD 2015 (1) The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegmen

  8. Slide 8: Clinical Book-to-Bill

    Clinical Book-to-Bill Total Clinical Q1 2015 Q2 2015 LTM Serviceable Backlog Rollforward Beginning Backlog $1,860 $1,926 $1,806 New Wins $380 $368 $1,446 Cancellations and Scope Changes, (net) ($90) ($117) ($290) Project Restart and (Delays), net ($5) ($1) ($130) Revenue Earned ($220) ($234) ($891)

  9. Slide 9: Commercial Performance

    Commercial Performance Net Revenues(1) ($ millions) $259 $493 $233 $442 Q2 2014 Q2 2015 YTD 2014 YTD 2015 Adjusted EBITDA(2) ($ millions) $42 $76 $30 $55 Q2 2014 Q2 2015 YTD 2014 YTD 2015 (1) The sum of the segments do not reconcile to Consolidated inVentiv Health due to eliminations of approximatel

  10. Slide 10: Appendix

    re Appendix -\inVentiv “ ="')Health

  11. Slide 11: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation For the Quarter and Last Six Months Ended June 30, 2015 ($ millions) QTD QTD YTD YTD Q2 2015 Q2 2014 Q2 2015 Q2 2014 Net Income (loss) from continuing operations ($30.0) ($47.5) ($75.0) ($93.5) Income tax provision (benefit) 2.7 5.8 7.3 7.7 Interest expense, net 57.1 5

  12. Slide 12: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation For the Quarter Ended June 30, 2015 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($30.0) Income tax provision (benefit) 2.7 Interest expense, net 57.1 Equity investment income (0.2) Operating Income $17.6

  13. Slide 13: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation For the Quarter Ended June 30, 2014 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($47.5) Income tax provision (benefit) 5.8 Interest expense, net 53.2 Equity investment income 0.2 Operating Income $3.5 $1

  14. Slide 14: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation For the Six Months Ended June 30, 2015 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($75.0) Income tax provision (benefit) 7.3 Interest expense, net 113.6 Equity investment income 1.3 Operating Income $32

  15. Slide 15: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation For the Six Months Ended June 30, 2014 ($ millions) inVentiv Clinical Commercial Corporate Health, Inc. Net Income (loss) from continuing operations ($93.5) Income tax provision (benefit) 7.7 Interest expense, net 105.7 Equity investment income 0.2 Operating Income $7.

  16. Slide 16: Adjusted EBITDA Footnotes

    Adjusted EBITDA Footnotes (a) Represents non-cash losses associated with the write-off of goodwill, intangible assets and other long-lived assets that affect the comparability of our operational results and for which an adjustment is made consistent with the terms of our debt instruments. (b) Repres

inVentiv Health — Q2 2015 Earnings Presentation on 6ix